Platelet prostanoid receptors

Pharmacology and Therapeutics

Volumn 72, Issue 3, 1996, Pages 171-191

  Armstrong, Roma A ^a  

^a QUEEN MARGARET UNIVERSITY   (United Kingdom)

Author keywords

human platelets; isoprostanes; PGD2 (DP) receptors; PGE2 (EP3) receptors; prostacyclin (IP) receptors; thromboxane (TP) receptors

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 15 HYDROXY 9ALPHA,11ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 [2 (2 CHLOROPHENYL) 4 (2 HYDROXYPHENYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; 7 (3 ACETYLBICYCLO[2.2.1]HEPT 2 YL) 5 HEPTENOIC ACID 4 PHENYLTHIOSEMICARBAZONE; 7 (3 FORMYLBICYCLO[2.2.1]HEPT 2 YL) 5 HEPTENOIC ACID 4 PHENYLSEMICARBAZONE; 7 [2 (BENZHYDRYLOXYIMINOMETHYL)BICYCLO[2.2.2]OCT 5 EN 3 YL] 5 HEPTENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; BMY 42393; CARBACYCLIN; CICAPROST; ILOPROST; OCTIMABATE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; RAMATROBAN; THROMBOXANE; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG; VAPIPROST;

CELL ACTIVATION; CELL MEMBRANE; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

BLOOD PLATELETS; HUMANS; RECEPTORS, EPOPROSTENOL; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, THROMBOXANE; SIGNAL TRANSDUCTION;

EID: 0030460491     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(96)00103-9     Document Type: Review

References (254)

1. Abramovitz, M., Boie, Y., Nguyen, T., Rushmore, T. H., Bayne, M. A., Metters, K. M., Slipetz, D. M. and Grygorczyk, R. (1994) Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269: 2632-2636.
2. 2 by human platelets. Thromb. Res. 11: 485-496.
3. Al-Sinawi, L. A. H., Mekki, A. Q., Hassan, S., Hedges, A., Burke, C., Moody, S. G. and O'Grady, J. (1985) Effect of a hydantoin prostaglandin analogue, BW 25C during oral dosing in man. Prostaglandins 29: 99-111.
4. Alt, U., Leigh, P. J., Wilkins, A. J., Morris, P. K. and MacDermot, J. (1986) Desensitisation of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br. J. Clin. Pharmacol. 22: 118-119.
5. 2. Biochem. Biophys. Res. Commun. 197: 263-270.
6. Andersen, N. H., Eggerman, T. L., Harker, L. A., Wilson, C. H. and De, B. (1980) On the multiplicity of platelet prostaglandin receptors. 1. Evaluation of competitive antagonism by aggregometry. Prostaglandins 19: 711-735.
7. 2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 116: 2903-2908.
8. Armstrong, R. A., Jones, R. L. and Wilson, N. H. (1983) Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br. J. Pharmacol. 79: 953-964.
9. Armstrong, R. A., Jones, R. L., Peesapati, V., Will, S. G. and Wilson, N. H. (1985a) Competitive antagonism at thromboxane receptors in human platelets. Br. J. Pharmacol. 84: 595-607.
10. 2α. Prostaglandins 29: 601-610.
11. Armstrong, R. A., Jones, R. L., MacDermot, J. and Wilson, N. H. (1986) Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br. J. Pharmacol. 87: 543-551.
12. Armstrong, R. A., Lawrence, R. A., Jones, R. L. and Wilson, N. H. (1989) Functional and ligand binding studies suggest heterogeneity of prostacyclin receptors. Br. J. Pharmacol. 97: 657-668.
13. 3H]-GR 32191 to the thromboxane (TP)-receptor of human platelets. Br. J. Pharmacol. 110: 539-547.
14. Ashby, B. (1992) Comparison of iloprost, cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets. Prostaglandins 43: 255-261.
15. Authi, K., Evendon, B. and Crawford, N. (1986) Metabolic and functional consequences of introducing inositol 1,4,5-triphosphate into saponin-permeabilised human platelets. Biochem. J. 223: 709-718.
16. 2 in saponin-permeabilized human platelets. FEBS Lett. 213: 95-101.
17. Awad, J. A., Morrow, J. D., Takahashi, K. and Roberts, L. J. (1993) Identification of non-cyclooxygenase-derived [F2-isoprostane] metabolites in human urine and plasma. J. Biol. Chem. 268: 4161-4169.
18. q. Biochem. J. 291: 235-240.
19. 1. Br. J. Pharmacol. 73: 225P.
20. 1 derivatives in the cardiovascular system. Br. J. Pharmacol. 84: 71-80.
21. Banno, Y., Nakashima, T., Kumada, T., Ebisawa, K., Nonomura, Y. and Nozawa, V. (1992) Effects of gelsolin on human platelet cytosolic phosphoinositide-phospholipase C isozymes. J. Biol. Chem. 267: 6488-6494.
22. 2 subtype. J. Biol. Chem. 269: 11873-11877.
23. 3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br. J. Pharmacol. 72: 435-441.
24. Boie, Y., Rushmore, T. H., Darmon-Goodwin, A., Grygorczyk, R., Slipetz, D. M., Metters, K. M. and Abramovitz, M. (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 269: 12173-12178.
25. Boie, Y., Sawyer, N., Slipetz, D. M., Metters, K. M. and Abramovitz, M. (1995) Molecular-cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270: 18910-18916.
26. 2 receptor. Biochem. Pharmacol. 45: 2071-2078.
27. 2 receptors by immunoaffinity chromatography employing anti-peptide and anti-receptor antibodies. J. Biol. Chem. 269: 6109-6116.
28. 2+ mobilisation and granule secretion in platelets. J. Biol. Chem. 260: 15172-15179.
29. Brass, L. F. and Shattil, S. J. (1982) Changes in surface-bound and exchangeable calcium during platelet activation. J. Clin. Invest. 257: 14000-14005.
30. 2 relaxes bovine coronary arteries by endothelium-dependent-nitric oxide-mediated cGMP formation. Circ. Res. 71: 1305-1313.
31. Brewster, A. G., Brown, G. R., Foubister, A. J., Jessup, R. and Smithers, M. J. (1988) The synthesis of a novel thromboxane receptor antagonist 4(Z)-6-(2-o-chlorophenyl-4-O-hydroxyphenyl-1,3-doxan-cis-6-yl) hexanoic acid, ICI 192605. Prostaglandins 36: 173-178.
32. 2 receptor. J. Biol. Chem. 269: 6163-6169.
33. 2. Circulation 72: 1208-1218.
34. 3 receptors. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 21, pp. 379-382, Samuelsson, B., Paoletti, R. and Ramwell, P. (eds.) Raven Press, New York.
35. Bundy, G. L. (1975) Synthesis of prostaglandin endoperoxide analogs. Tetrahedron Lett. 24: 1957-1960.
36. Bundy, G. L., Morton, D. R., Peterson, D. C., Nishizawa, E. E. and Miller, W. L. (1983) Synthesis and platelet aggregation inhibiting activity of prostglandin D analogues. Am. Chem. Soc. 26: 790-799.
37. Burke, S. E., Lefer, A. M., Nicolaou, K. C., Smith, G. M. and Smith. J. B. (1983) Responses of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br. J. Pharmacol. 78: 287-292.
38. Caldwell. A. G., Harris, C. J., Stepney, R. and Whittaker, N. (1979) Hydantoin prostaglandin analogues, potent and selective inhibitors of platelet aggregation. J. Chem. Soc. Chem. Commun. 101: 561-562.
39. 2 on some isolated smooth muscle preparations. Br. J. Pharmacol. 78: 773-778.
40. 2-sensitive receptors. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 17A, pp. 467-470, Samuelsson, B., Paoletti, R. and Ramwell, P. (eds.) Raven Press, New York.
41. Coleman, R. A., Grix, S. P., Head, S. A., Louttit, J. B., Mallett, A. and Sheldrick, R. L. G. (1994a) A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47: 151-168.
42. Coleman, R. A., Smith, W. L. and Narumiya, S. (1994b) International Union of Pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmac. Rev. 46: 205-229.
43. 4-antagonist, AH 22921. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 23, pp. 241-246, Samuelsson, B., Paoletti, R. and Ramwell, P. (eds.) Raven Press, New York.
44. Coller, B. S. (1992) Antiplatelet agents in the prevention and therapy of thrombosis. Annu. Rev. Med. 43: 171-180.
45. Collins, P. W., Pappo, R. and Dajani, E. Z. (1985) Chemistry and synthetic development of misoprostol. Dig. Dis. Sci. 30 (Suppl.): 114S.
46. Conti, M. A. and Adelstein, R. S. (1981) The relationship between calmodulin binding and phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3′5′cAMP-dependent protein kinase. J. Biol. Chem. 256: 3178-3181.
47. Cooper, B., Schafer, A. I., Puchalsky, D. and Hanlin, R. I. (1979) Desensitisation of prostaglandin-activated platelet adenylate cyclase. Prostaglandins 17: 561-571.
48. 2. J. Am. Chem. Soc. 98: 6417-6418.
49. Corsini, A., Folco, G. C., Fumagalli, R., Nicosia, S., Noe, M. A. and Oliva, D. (1987) (5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br. J. Pharmacol. 90: 255-261.
50. DeWitt, D. L. and Smith, W. L. (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. USA 85: 1412-1416.
51. Di Minno, G., Bertele, V., Bianchi, L., Cerletti, C., Dejana, E., de Gaetano, G. and Silver, M. J. (1981) Effects of an epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb. Haemost. 45: 103-106.
52. Dong, Y. J., Jones, R. L. and Wilson, N. H. (1986) Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br. J. Pharmacol. 87: 97-107.
53. 2 receptor subtypes; a radioligand binding study of human platelets. J. Clin. Invest. 84: 1883-1891.
54. 2 receptors. Am. J. Physiol. 29: H327-H334.
55. 2) responsiveness of platelets. Br. J. Pharmacol. 90: 501-510.
56. 2 on human gel-filtered platelets. J. Pharmacol. Exp. Ther. 236: 568-573.
57. Farese, R. V., Rosic, N., Babischkin, J., Farese, M. G., Foster, R. and Davis, J. S. (1986) Dual activation of the inositol-triphosphate-calcium and cyclic nucleotide intracellular signaling systems by adrenocorticotrophin in rat adrenal cells. Biochem. Biophys. Res. Commun. 135: 742-748.
58. Faull, A. W., Brewster, A. G., Brown, G. R., Smithers, M. J. and Jackson, R. (1995) Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl]alkenoic acids. J. Med. Chem. 38: 686-694.
59. 1, forskolin). Biochem. Biophys. Res. Commun. 113: 598-604.
60. Ferrell, J. E., Jr. and Martin, G. S. (1989) Tyrosine-specific protein phosphorylation is regulated by glycoprotein IIb/IIIa in platelets. Proc. Natl. Acad. Sci. USA 86: 2234-2238.
61. FitzGerald, G. A. and Meagher, E. A. (1994) Antiplatelet drugs. Eur. J. Clin. Invest. 24: 46-49.
62. Fox, J. E. B. and Phillips, D. R. (1982) Role of phosphorylation in mediating the association of myosin with the cytoskeletal structures in human platelets. J. Biol. Chem. 257: 4120-4126.
63. 1. Possible role of a membrane polypeptide in the regulation of calcium transport. Biochem. J. 184: 651-661.
64. 1 subtype. J. Biol. Chem. 268: 26767-26772.
65. 2 receptor allows discrimination between agonist and antagonist binding sites. Mol. Pharmacol. 44: 934-939.
66. Gardiner, P. J. (1986) Characterization of prostanoid relaxant/ inhibitory receptors using a highly selective agonist, TR 4979. Br. J. Pharmacol. 87: 45-56.
67. Gerrard, J. N., Peller, J. D., Krick, T. P. and White, J. G. (1977) Cyclic AMP and platelet prostaglandin synthesis. Prostaglandins 14: 39-50.
68. 2. Prostaglandins 35: 277-300.
69. Giles, H., Leff, P., Bolofo, M. L., Kelly, M. G. and Robertson, A. D. (1989) The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol. 96: 291-300.
70. 2. Br. J. Pharmacol. 104: 541-549.
71. Golden, A., Brugge, J. S. and Shattil, S. J. (1990) Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins. J. Cell Biol. 111: 3117-3127.
72. +-dependent p-nitrophenyl phosphatase and adenylate cyclase by using one-step method in human washed platelets. Histochemistry 97: 503-507.
73. Gorman, R. R., Bunting, S. and Miller, O. V. (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377-388.
74. 2 and inhibitors of platelet aggregation which act through cyclic AMP. Eur. J. Pharmacol. 194: 63-70.
75. Gresele, P., Deckmyn, H., Nenci, G. G. and Ver Mylen, J. (1991) Thromboxane synthetase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. 12: 158-163.
76. 3H] iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci. Rep. 4: 941-918.
77. 2 receptor antagonists. Med. Res. Rev. 11: 503-579.
78. 2+, diacylglycerol and thromboxane with particular reference to ADP stimulation. Adv. Exp. Med. Biol. 192: 145-162.
79. 2. Adv. Prostaglandin Thromboxane Leukot. Res. 11: 319-322.
80. Hamberg, M. and Samuelsson, B. (1974) Prostaglandin endoperoxides. Novel transformations of arachidonic acid in platelets. Proc. Natl. Acad. Sci. USA 71: 3400-3404.
81. Hamberg, M., Svensson, J. and Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72: 2994-2998.
82. Hannun, Y. A., Greenberg, C. S. and Bell, R. M. (1987) Sphingosine inhibition of agonist-dependent secretion and activation of human platelets implies that protein kinase C is a necessary and common event of the signal transduction pathway. J. Biol. Chem. 262: 13620-13626.
83. 2-stimulated cyclic AMP production by rat isolated enteroocytes. J. Pharm. Pharmacol. 84: 68.
84. Hathaway, D. R., Eaton, C. R. and Adelstein, R. S. (1981) Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. Nature 291: 252-254.
85. 2 in man. Prostaglandins 28: 755-767.
86. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 245: 786-792.
87. Hirata, M., Hyashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Naknishi, S. and Narumiya, S. (1991) Cloning and expression of cDNA for a human thromboxane receptor. Nature 349: 617-620.
88. Hirata, M., Kakizuka, A., Aizawa, M., Ushikubi, F. and Narumiya, S. (1994) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. USA 91: 11192-11196.
89. Hla, T. and Neilson, K. (1992) Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89: 7384-7388.
90. 2 subtype. J. Biol. Chem. 268: 7759-7762.
91. Houslay, M. D., Bojanic, D. and Wilson, A. (1986) Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. Biochem. J. 234: 737-740.
92. 2. Biochem. Biophys. Res. Commun. 170: 259-263.
93. 1 in cDNA-transfected Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 204: 303-309.
94. 2: a biochemical perspective. Prostaglandins Leukot. Essent. Fatty Acids 37: 219-234.
95. 1]19-(3-azidophenyl)-20-norisocarbacyclin, an irreversible specific photoaffinity probe. J. Biol. Chem. 267: 20326-20330.
96. 2 receptors. Circ. Res. 62: 494-505.
97. 1-receptor antagonist CP-96,345 partially inhibits cicaprost-induced contractions of the guinea-pig ileum. Pharmacol. Commun. 3: 147-152.
98. Jones, R. L., Wilson, N. H., Armstrong, R. A., Peesapati, V. and Smith, G. M. (1983) Effects of thromboxane antagonist EP045 on platelet aggregation. Adv. Prostaglandin Thromboxane Leukot. Res. 11: 345-349.
99. Jones, R. L., Wilson, N. H., Armstrong, R. A. and Dong, Y. J. (1984) Receptors for thromboxanes and prostaglandins, In: Proceedings of the 9th International Congress of Pharmacology, Vol. 2, pp. 293-301, Paton, W., Mitchell, J. and Turner, P. (eds.) Macmillan Press, London.
100. Jones, R. L., Wilson, N. H., Marr, C. J., Muir, G. and Armstrong, R. A. (1993) Diphenylmethylazine prostanoids with prostacyclin-like actions on human platelets. J. Lipid Mediators 6: 405-410.
101. Jorgensen, K. A. (1982) Studies on the biological balance between thromboxanes and prostacyclins in relation to the platelet-vessel wall interactions. Dan. Med Bull. 29: 169-197.
102. 2) on platelet aggregation. Thromb. Res. 19: 877-881.
103. 2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ. Res. 49: 685-700.
104. 2 subtype. Invest. Ophthalmol. Vis. Sci. 82: 360-365.
105. Kang, K. H., Morrow, J. D., Roberts, L. J., Newman, J. H. and Banjeree, M. (1993) Airway and vascular effects of 8-epi-prostaglandin-F2-a isolated perfused lung. J. Appl. Physiol. 74: 460-465.
106. 2+-accumulating vesicles. Biochim. Biophys. Acta 558: 344-347.
107. 2 receptor antagonists. Thromb. Res. 41: 471-481.
108. Keery, R. J. and Lumley, P. (1988) AH 6809, a prostaglandin DP-receptor blocking drug on human platelets. Br. J. Pharmacol. 94: 745-754.
109. Kennedy, I., Coleman, R. A., Humphrey, P. P. A., Levy, G. P. and Lumley, P. (1982) Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 24: 667-689.
110. Kinsella, B. T., O'Mahony, D. J. and FitzGerald, G. A. (1993) Regulation of the thromboxane receptor by phosphorylation in vivo. Blood 82: 610.
111. Kinsella, B. T., O'Mahony, D. J., Lawson, J. A., Pratico, D. and FitzGerald, G. A. (1995) Cellular activation of thromboxane receptors. Ann. NY Acad. Sci. 714: 270-278.
112. 2 receptor of the antagonist S-145. Br. J. Pharmacol. 103: 1883-1888.
113. Kulmacz, R. J. Pendleton, R. B. and Lands, W. E. M. (1994) Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. J. Biol. Chem. 269: 5527-5536.
114. 2α receptor. FEBS Lett. 355: 317-325.
115. Lawrence, R. A. and Jones, R. L. (1989) AH 6809 distinguishes two types of direct contractile action for prostanoids on guinea-pig ileum longitudinal muscle. Br. J. Pharmacol. Proc. Suppl. 96: 63P.
116. Lawrence, R. A. and Jones, R. L. (1992) Investigation of the prostaglandin E (EP-) subtype mediating relaxation of the rabbit jugular vein. Br. J. Pharmacol. 105: 817-824.
117. Lawrence, R. A., Jones, R. L. and Wilson, N. H. (1992) Characterisation of receptors involved in the direct and indirect actions of prostaglandin E and I on the guinea pig ileum. Br. J. Pharmacol. 105: 272-278.
118. 2. Proc. Natl. Acad. Sci. USA 77: 1706-1710.
119. Leigh, P. J., Cramp, W. A. and MacDermot, J. (1984) Identification of the prostacyclin receptor by radiation inactivation. J. Biol. Chem. 259: 12431-12436.
120. 3H] U 46619 to washed human platelets. Prostagtandins 33: 789-797.
121. 2 receptors by the mimetic U46619. J. Pharmacol. Exp. Ther. 247: 1133-1138.
122. 2-sensitive adenylate cyclase in human platelets. Prostaglandins 27: 321-333.
123. 2 receptor blocking drug on platelets and airways smooth muscle in vitro. Br. J. Pharmacol. 97: 783-794.
124. MacIntyre, D. E. and Gordon, J. (1977) Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb. Res. 11: 706-713.
125. 2+ flux in human platelet activation. Adv. Exp. Med. Biol. 192: 127-144.
126. Maier, J. A. M., Hla, T. and Macaig, T. (1990) Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J. Biol. Chem. 265: 10805-10808.
127. Malmsten, C. (1975) Some biological effects of prostaglandin endoperoxide analogues. Life Sci. 18: 169-176.
128. 2) in human platelets. Biochem. Biophys. Res. Commun. 68: 569-576.
129. Masotti, G., Poggesi, I., Galanti, G., Abbate, R. and Neri Serneri, G. G. (1979) Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet ii: 1213-1216.
130. Matthews, J. S. and Jones, R. L. (1993) Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br. J. Pharmacol. 108: 363-369.
131. Maurice, D. H. and Haslam, R. J. (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37: 671-681.
132. 2 receptor agonist and antagonist binding in human platelets. J. Biol. Chem. 266: 13752-13758.
133. 2 in regulation of cyclic-AMP and aggregation in human platelets. Evidence for a common prostaglandin receptor. J. Lab. Clin. Med. 84: 111-121.
134. 2 receptor antagonist on airway smooth muscle in vitro. Br. J. Pharmacol. 104: 585-590.
135. Meanwell, N. A., Romine, J. L. and Seiler, S. M. (1994) Non-prostanoid prostacyclin mimetics. Drugs Future 19: 361-385.
136. Merlie, J. P., Pagan, D., Mudd, J. and Needleman, P. (1988) Isolation and characterisation of the complementary DNA for sheep seminal vesicle prostaglandin synthase (cyclooxygenase). J. Biol. Chem. 263: 3550-3553.
137. Merritt, J. R., Brown, A. M., Bund, S., Cooper, D. G., Egan, J. W., Hallam, T. J., Heagerty, A. M., Hickey, D. M. B., Kaumann, A. M., Keen, M., Kelly, E., Kenney, C. A., Nichols, A. J., Smith, E. F., II, Swayne, G. T. G., MacDermot, J. and Rink, T. J. (1991a) Primate vascular responses to octimabate, a non-prostanoid agonist at the prostacyclin receptor. Br. J. Pharmacol. 102: 260-266.
138. Merritt, J. R., Hallam, T. J., Brown, A. M., Boyfield, I., Cooper, D. G., Hickey, D. M. B., Jaxa-Chamiec, A. A., Kaumann, A. J., Keen, M., Kelly, E., Kozlowski, U., Lynham, J. A., Moores, K. E., Murray, K. J., MacDermot, J. and Rink, T. J. (1991b) Octimabate, a potent non-prostanoid inhibitor of platelet aggregation acts via the prostacyclin receptor. Br. J. Pharmacol. 102: 251-259.
139. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 210: 134-140.
140. 2. Thromb. Res. 5: 401-412.
141. Milne, S. A., Armstrong, R. A. and Woodward, D. F. (1995) Investigation of prostanoid EP receptors in rabbit jugular and pig saphenous veins. Prostaglandins 49: 225-237.
142. 2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation. Am. Heart J. 129: 873-879.
143. 3-and DP-receptors. Br. J. Pharmacol. 111: 733-738.
144. Moncada, S. (1982) Biological importance of prostacyclin. Br. J. Pharmacol. 76:3-31.
145. Moncada, S. and Vane, J. R. (1980) Prostacyclin in the cardiovascular system. Adv. Prostaglandin Thromboxane Leukot. Res., 6: 43-60.
146. Moncada, S., Gryglewski, R. J., Bunting, S. and Vane, J. R. (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature 263: 663-665.
147. 2 analogue (U44619) on human platelets. Am. J. Physiol. 253: H1035-H1043.
148. 2 with differential effects on platelets and blood vessels. Proc. Natl. Acad. Sci. USA 86: 5600-5604.
149. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalysed mechanism. Proc. Natl. Acad. Sci. USA 87: 9383-9387.
150. 2-iso prostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 89: 10721-10725.
151. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44: 155-163.
152. Morrow, J. D., Minton, T. A., Mukundan, C. R., Campbell, M. D., Zackert, W. E., Daniel, V. C., Badr, K. F., Blair, I. A. and Roberts, J. L. (1994) Free radical-induced generation of isoprostanes m vivo. J. Biol. Chem. 269: 4317-4326.
153. Murray, R. and FitzGerald, G. A. (1989) Regulation of thromboxane receptor activation in human platelets. Proc. Natl. Acad. Sci. USA 86: 124-128.
154. Nakagawa, O., Tanaka, I., Usui, T., Harada, M., Sasaki, Y., Itoh, H., Yoshimasa, T., Namba, T., Narumiya, S. and Nakao, K. (1994) Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90: 1643-1647.
155. 2 receptor: cDNA cloning, expression and northern blot analysis. Biochem. Biophys. Res. Commun. 184: 1197-1203.
156. 3 determines G-protein specificity. Nature 365: 166-170.
157. Namba, T., Oida, H., Sugimoto, Y., Kakizuka, A., Negishi, M., Ichikawa, A. and Narumiya, S. (1994) cDNA cloning of a mouse prostacyclin receptor: multiple signaling pathways and expression in thymic medulla. J. Biol. Chem. 269: 9986-9992.
158. Narumiya, S., Hirata, N., Namba, T., Hayashi, Y., Ushikubi, F., Sugimoto, Y., Negishi, M. and Ichikawa, A. (1993) Structure and function of prostanoid receptors. J. Lipid Mediat. 6: 155-161.
159. Needleman, P. J., Turk, B. A., Jakschik, A. R., Morrison, A. R. and Lefkowith, J. B. (1986) Arachidonic acid metabolism. Annu. Rev. Biochem. 55: 69-102.
160. Negishi, M., Ito, S. and Hayaishi, O. (1989) Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner. J. Biol. Chem. 264: 4986-4991.
161. o. J. Biol. Chem. 268: 26067-26070.
162. 3 receptor. Prostaglandins 48: 275-283.
163. 2-receptor agonist. Cardiovasc. Drug Rev. 11: 165-179.
164. Nickolson, R. C., Town, M. H. and Vorbruggen, H. (1985) Prostacyclin analogs. Med. Res. Rev. 5: 1-53.
165. 2, a selective inhibitor of coronary artery constriction, platelet aggregation and thromboxane formation. Proc. Natl. Acad. Sci. USA 76: 2566-2570.
166. Nugteren, D. H. and Haxelhof, E. (1973) Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta 326: 448-461.
167. 2 receptor gene. J. Biol. Chem. 268: 25253-25259.
168. Oda, A., Daley, J. F., Cabral, C. C., Smith, M., Kang, J. and Salzman, E. W. (1992a) Heterogeneity in filamentous actin content among individual blood platelets. Blood 79: 920-927.
169. Oda, A., Druker, B. J., Smith, M. and Salzman, E. W. (1992b) Association of pp60src with triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerisation. J. Biol. Chem. 267: 20075-20081.
170. 2 by human platelets. Prostaglandins 13: 225-233.
171. 2 and thrombin receptors in human platelets. Proc. Natl. Acad. Sci. USA 91: 504-508.
172. Ogletree, M. L. and Allen, G. T. (1992) Interspecies differences in thromboxane receptors: studies in rat and guinea pig smooth muscles. J. Pharmacol. Exp. Ther. 260: 789-794.
173. Ogletree, M. L., Harris, D. N., Greenberg, R., Haslanger, M. F. and Nakane, M. (1985) Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234: 435-441.
174. 2/ prostaglandin endoperoxide receptor antagonist. J. Pharmacol. Exp. Ther. 264: 570-578.
175. 2+-transporting membrane vesicle fraction derived from human platelets. J. Biol. Chem. 260: 956-962.
176. Peerschke, E. I. B. (1985) The platelet fibrinogen receptor. Semin. Hematol. 22: 241-259.
177. Pierce, K. L., Gil, D. W., Woodward, D. F. and Regan, J. W. (1995) Cloning of human prostanoid receptors. Trends Pharmacol. Sci. 16: 253-256.
178. Plevin, R., Owen, P. J., Marriott, D. B., Jones, J. A. and Boarder, M. R. (1990) Role of phosphoinositide turnover and cyclic AMP accumulation in prostaglandin-stimulated noradrenaline release from cultured adrenal chromaffin cells. J. Pharmacol. Exp. Ther. 252: 1296-1303.
179. Poll, C. and Westwick, J. (1986) Phorbol esters modulate thrombin-operated calcium mobilisation and dense granule release in human platelets. Biochim. Biophys. Acta 886: 434-440.
180. Pollock, W. K., Armstrong, R. A., Brydon, L., Jones, R. L. and MacIntyre, D. E. (1984) Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Biochem. J. 219: 833-842.
181. Pratico, D., Lawson, J. A. and FitzGerald, G. A. (1994) Cyclooxygenase-dependent formation of the isoprostane 8-epi prostaglandin F2 alpha. Ann. NY Acad. Sci. 744: 139-145.
182. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J. Biol. Chem. 269: 11938-1944.
183. 2, that inhibits platelet aggregation and constricts blood vessels. J. Biol. Chem. 260: 14621-14625.
184. Qian, Y. and Jones, R. L. (1995) Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission. Br. J. Pharmacol. 115: 163-171.
185. Radomski, M. W., Rees, D. D., Dutra, A. and Moncada, S. (1992) S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol. 107: 745-749.
186. 2 receptor. J. Biol. Chem. 269: 19256-19261.
187. 3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol. 112: 377-385.
188. 2 subtype. Mol. Pharmacol. 46: 213-220.
189. Reimer, R., Heim, H. K., Muallem, R., Odes, H. S. and Sewing, K. F. (1992) Effects of EP-receptor subtype specific agonists and other prostanoids on adenylate cyclase activity of duodenal epithelial cells. Prostaglandins 44: 485-493.
190. 2 biologically active prostaglandin formed in vivo in humans. Clin. Res. 33: 162A.
191. Rucker, W. and Schror, K. (1983) Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochem. Pharmacol. 32: 2405-2410.
192. Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammerstrom, S. and Malmsten, C. (1978) Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47: 997-1029.
193. Sano, K., Takai, Y., Yamanishi, J. and Nishizuka, Y. (1983) A role of calcium-activated phospholipid dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. J. Biol. Chem. 258: 2010-2013.
194. 3 receptor. Prostaglandins Leukot. Essent. Fatty Acids 49: 939-943.
195. 2. J. Biol. Chem. 254: 2914-2917.
196. 2-receptors and c-AMP levels in platelets and femoral arteries. Acta Ther. 6: 37-42.
197. 2. Eur. J. Biochem. 228: 23-30.
198. 2 in vitro. Naunyn Schmiedebergs Arch. Pharmacol. 316: 232-255.
199. 2 receptors by diethylpyrocarbonate. Biochem. Pharmacol. 49: 921-927.
200. Schumacher, W. A., Heran, C. L., Steinbacher, T. E., Youssef, S. and Ogletree, M. L. (1993) Superior activity of a thromboxane receptor antagonist compared to aspirin in rat models of arterial and venous thrombosis. J. Cardiovasc. Pharmacol. 22: 526-533.
201. Schwaner, I., Offermanns, S., Spicher, K., Seifert, R. and Schultz, G. (1995) Differential activation of Gi and Gs by E-and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL. Biochim. Biophys. Acta 1265: 8-14.
202. Seiler, S., Brassard, C. L., Arnold, A. J., Meanwell, N. A., Fleming, J. S. and Keely, S. L. (1990) Octimabate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J. Pharmacol. Exp. Ther. 255: 1021-1026.
203. Seiler, S. M., Brassard, C. L., Federici, M. A., Buchanan, J. O., Zavoico, G. B., Fleming, J. S. and Meanwell, N. A. (1994a) 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1) inhibition of platelet aggregation and mechanism of action. Thromb. Res. 74:115-123.
204. Seiler, S. M., Buchanan, J. O., Schumacher, W. A., Zavoico, G. B., Gamberdella, M., Fleming, J. S. and Meanwell, N. A. (1994b) 2-[3-[2-(4,5-diphenyl-2-oxazoiyl)ethyl]phenoxy] acetic acid (BMY 42393): 2) oral activity and efficacy in animal models of arterial thrombosis. Thromb. Res. 74: 125-133.
205. Shah, A., Pickles, H., Joshi, M., Webster, A. and O'Grady, A. (1984) Effects of single oral dose administration of a hydantoin prostaglandin analogue BW 245C in man. Life Sci. 34: 2281-2286.
206. 1 and IP receptor agonist. Br. J. Pharmacol. 94: 334P.
207. q family. J. Biol. Chem. 266: 9309-9313.
208. 2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br. J. Clin. Pharmacol. 15: 77-81.
209. Shimizu, T., Yamamoto, S. and Hayaishi, O. (1979) Purification and properties of prostaglandin D synthase from rat brain. J. Biol. Chem. 254: 5222-5228.
210. 2 and aspirin on the secondary aggregation of human platelets. Nature 236: 45-46.
211. 2 on human platelets. Biochem. Biophys. Res. Commun. 90: 291-296.
212. Siess, W., Siegel, F. L. and Lapetina, E. G. (1983) Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J. Biol. Chem. 258: 11236-11242.
213. Simpson, P. J., Mickelson, J., Fantone, J. C., Gallacher, K. P. and Lucchesi, B. R. (1987) Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ. Res. 60: 666-673.
214. 2 during long term intaarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenom? Prostaglandins 21: 49-51.
215. 2 inhibits the aggregation of human platelets. Thromb. Res. 5: 291-299.
216. Smith, W. L. (1989) The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259: 315-324.
217. 2 intrinsic activity. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System, pp. 485-491, Schror, K. (ed.) Karger, Basel.
218. 3 subtype. J. Biol. Chem. 267: 6463-6466.
219. 3 receptor with different carboxyl-terminal domains. J. Biol. Chem. 268: 2712-2718.
220. Sugimoto, Y., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., Kakizuka, A., Narumiya, S. and Ichikawa, A. (1994) Cloning and expression of a cDNA for mouse prostaglandin F receptor. J. Biol. Chem. 269: 1356-1360.
221. 2α, in the rat. J. Clin. Invest. 90: 136-141.
222. Takahashi, K., Fukunaga, M., Makita, N. and Badr, K. F. (1993) Involvement of distinct F2-isoprostane receptors in 8-epi-prostaglandin F2-alpha actions on rat vascular smooth muscle cells. Circulation 88: 433.
223. 2 analogues in human platelets. J. Biol. Chem. 265: 6836-6844.
224. Takai, Y., Kishimoto, A., Kikkawa, U., Mori, T. and Nishizuka, Y. (1979) Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. Biochem. Biophys. Res. Commun. 91: 1218-1224.
225. Takai, Y., Kaibuchi, K., Sano, K. and Nishizuka, Y. (1982) Counteraction of calcium-activated phospholipid-dependent protein kinase activation by adenosine 3′5′-monophosphate and guanosine 3′5′-monophosphate in platelets. Biochem. J. 91: 403-406.
226. Talpain, E., Armstrong, R. A., Coleman, R. A. and Vardey, C. J. (1995) Characterisation of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br. J. Pharmacol. 114: 1459-1465.
227. Tateson, J. B., Moncada, S. and Vane, J. R. (1977) Effect of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13: 389-396.
228. Tauber, U., Elger, W. and Nieuweboer, B. (1988) Systemic availability and abortion-inducing effects of nocloprost after intravenous, subcutaneous and intragastric administration to pregnant guinea-pigs. Prostaglandins 36: 151-162.
229. 2 receptor. Prostaglandins 35: 855-868.
230. Thompson, N. T. and Scrutton, M. C. (1985) Intracellular calcium fluxes in human platelets. Eur. J. Biochem. 147: 421-427.
231. Toh, H., Ichikawa, A. and Narumiya, S. (1995) Molecular evolution of receptors for eicosanoids. FEBS Lett. 361: 17-21.
232. Town, M. H., Schillinger, E., Speckenbach, A. and Prior, G. (1982) Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioligand. Prostaglandins 24: 61-72.
233. 2 receptors. Prostaglandins 25: 13-28.
234. 2 and BW 245C activation of human platelet adenylate cyclase. Br. J. Pharmacol. 96: 301-306.
235. Tsai, A-L., Hsu, M-J., Vijjeswarapu, H. and Wu, K. K. (1989) Solubilisation of prostacyclin membrane receptors from human platelets. J. Biol. Chem. 264: 61-67.
236. Tsai, B. S., Kessler, L. K. and Egofske, P. (1985) Antisecretory activity and metabolism of misoprostol (SC-29333) in isolated canine parietal cells. Gastroenterology 88: 1618.
237. 2 (TP-) receptors: evidence from anatagonist but not agonist potency measurements. Br. J. Pharmacol. 102: 607-614.
238. 2 and hydantoin analogues. Prostaglandins 27: 683-695.
239. Ueno, Y., Shigenobu, K. and Nishio, S. (1993) Effects of beraprost on the transmembrane potentials of guinea-pig ventricular muscles during normoxia and hypoxia-reoxygenation. Br. J. Pharmacol. 109: 1014-1019.
240. 2 receptor from human blood platelets. J. Biol. Chem. 264: 16496-16501.
241. Vassaux, G., Gaillard, D., Ailhaud, G. and Negrel, R. (1992) Prostacyclin is a specific effector of adipose cell differentiation. J. Biol. Chem. 267: 11092-11097.
242. Waldmann, R., Bauer, S., Gobel, C., Hofmann, F., Jakobs, K. H. and Walter, U. (1986) Demonstration of cGMP-dependent protein kinase and cGMP-dependent phosphorylation in cell-free extracts of platelets. Eur. J. Biochem. 158: 203-210.
243. 1 subtype of prostaglandin E receptor. J. Biol. Chem. 268: 20175-20178.
244. 2 receptors from canine renal medulla: evidence for physical association of the receptor protein with the inhibitory guanine nucleotide-binding protein. Biochem. Biophys. Acta 1074: 398-405.
245. Watson, S. P., McConnel, R. T. and Lapetina, E. G. (1985) Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role for lysophosphatidic acid. Biochem. J. 232: 61-66.
246. Whittle, B. J. R. and Moncada, S. (1985) Platelet actions of stable carbocyclic analogues of prostacyclin. Circulation 72: 1219-1225.
247. Whittle, B. J. R., Moncada, S., Whiting, F. and Vane, J. R. (1980) Carbacyclin - a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 19: 605-627.
248. Whittle, B. J. R., Moncada, S., Mullane, K. and Vane, J. R. (1983) Platelet and cardiovascular activity of the hydantoin BW 245C, a potent prostaglandin analogue. Prostaglandins 25: 205-223.
249. Wilson, N. H., Jones, R. L., Marr, C. G. and Muir, G. (1988) Synthesis of oxabicyclo[2.2.1]heptane prostanoids having thromboxane-like activity at sub-nanomolar concentrations. Eur. J. Med. Chem. 23: 359-364.
250. Woo, S. K., Roszkowski, A. P., Waterbury, L. D. and Garay, G. L. (1986) Gastric mucosal binding studies with enprostil: a potent anti-ulcer prostaglandin. Prostaglandins 32: 243-257.
251. Wu, H., Turner, J. T. and Halenda, S. P. (1991) Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells. J. Pharmacol. Exp. Ther. 258: 607-612.
252. Xie, W., Chipman, J. G., Robertson, D. L., Erikson, R. L. and Simmons, D. L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA 88: 2692-2696.
253. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 270: 1192-1196.
254. Yousufzai, S. Y. K., Chen, A-L. and Abdel-Latif, A. A. (1988) Species differences in the effects of prostaglandins on inositol triphosphate accumulation, phosphatidic acid formation, myosin light chain phosphorylation and contraction in iris sphincter of the mammalian eye: interaction with the cyclic AMP system. J. Pharmacol. Exp. Ther. 247: 1064-1072.